Swiss National Bank Sells 42,480 Shares of Catalent, Inc. (NYSE:CTLT)

Posted by Defense World Staff on May 12th, 2023

Swiss National Bank reduced its stake in Catalent, Inc. (NYSE:CTLT – Get Rating) by 5.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 694,500 shares of the company’s stock after selling 42,480 shares during the quarter. Swiss National Bank owned 0.39% of Catalent worth $31,259,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Cetera Advisor Networks LLC boosted its holdings in Catalent by 7.1% in the 1st quarter. Cetera Advisor Networks LLC now owns 1,953 shares of the company’s stock valued at $217,000 after purchasing an additional 130 shares during the period. Private Advisor Group LLC increased its position in Catalent by 18.0% during the 1st quarter. Private Advisor Group LLC now owns 2,957 shares of the company’s stock worth $328,000 after purchasing an additional 452 shares in the last quarter. Panagora Asset Management Inc. increased its position in Catalent by 125.8% in the 1st quarter. Panagora Asset Management Inc. now owns 12,979 shares of the company’s stock valued at $1,439,000 after acquiring an additional 7,231 shares during the period. Yousif Capital Management LLC increased its position in shares of Catalent by 2.0% during the first quarter. Yousif Capital Management LLC now owns 24,561 shares of the company’s stock worth $2,724,000 after buying an additional 470 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of Catalent by 1.8% during the first quarter. Dimensional Fund Advisors LP now owns 991,019 shares of the company’s stock worth $109,904,000 after buying an additional 17,813 shares during the period. 99.38% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Mario Gargiulo sold 678 shares of the stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $49.86, for a total value of $33,805.08. Following the completion of the transaction, the senior vice president now directly owns 5,676 shares of the company’s stock, valued at $283,005.36. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Catalent news, insider Manja Boerman sold 1,446 shares of the firm’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $49.86, for a total transaction of $72,097.56. Following the completion of the transaction, the insider now owns 14,414 shares of the company’s stock, valued at $718,682.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mario Gargiulo sold 678 shares of the firm’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $49.86, for a total transaction of $33,805.08. Following the sale, the senior vice president now directly owns 5,676 shares of the company’s stock, valued at approximately $283,005.36. The disclosure for this sale can be found here. 0.58% of the stock is owned by insiders.

Catalent Price Performance

Shares of Catalent stock opened at $34.19 on Friday. Catalent, Inc. has a 52-week low of $32.41 and a 52-week high of $115.33. The stock has a market capitalization of $6.16 billion, a price-to-earnings ratio of 15.13, a price-to-earnings-growth ratio of 2.38 and a beta of 1.17. The company has a fifty day moving average of $57.51 and a 200-day moving average of $54.47. The company has a debt-to-equity ratio of 0.86, a quick ratio of 1.38 and a current ratio of 1.91.

Catalent (NYSE:CTLT – Get Rating) last posted its earnings results on Tuesday, February 7th. The company reported $0.62 earnings per share for the quarter, missing analysts’ consensus estimates of $0.64 by ($0.02). The firm had revenue of $1.15 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Catalent had a return on equity of 11.40% and a net margin of 8.62%. Equities research analysts expect that Catalent, Inc. will post 2.6 EPS for the current year.

Wall Street Analysts Forecast Growth

CTLT has been the topic of a number of recent research reports. Robert W. Baird lowered shares of Catalent from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $82.00 to $53.00 in a research note on Monday, April 17th. StockNews.com upgraded shares of Catalent to a “sell” rating in a report on Saturday, April 15th. Morgan Stanley boosted their price target on shares of Catalent from $81.00 to $85.00 and gave the stock an “overweight” rating in a report on Thursday, February 9th. Royal Bank of Canada cut their price target on shares of Catalent from $58.00 to $41.00 in a report on Monday. Finally, Bank of America cut shares of Catalent from a “neutral” rating to an “underperform” rating and set a $28.00 price target on the stock. in a report on Monday. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Catalent has an average rating of “Hold” and an average target price of $77.40.

Catalent Profile

(Get Rating)

Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.